Denali Therapeutics Inc.
DNLI· Nasdaq
Released Feb 26, 2026, after the close
10-K filed Feb 26, 2026, 57 days after period end · 0001714899-26-000021
derived · Computed from the longer spans the company filed.
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $10.26M |
| Net Income | -$128.55M |
Denali Therapeutics Inc. · CIK 1714899 · Engraved from SEC EDGAR
| -$114.75M |
| -$119.47M |
| -$98.68M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.